YD Bio Limited (YDES)
NASDAQ:YDES
Want to see YDES full AI Analyst Report?
YDES Stock Chart & Stats
$5.02
$0.22(4.58%)
―
--
Day’s Range― - ―
52-Week Range$4.73 - $25.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)91.42K
Market Cap
$354.02M
Enterprise Value$354.02M
Total Cash (Recent Filing)$6.31K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding70,521,360
10 Day Avg. Volume96,756
30 Day Avg. Volume91,419
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)7.57
Price to Sales (P/S)97.81
P/FCF Ratio-10.51
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-118.53
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Equity BaseExtremely low leverage reduces solvency and refinancing risk, giving management durable financial flexibility to fund R&D, clinical programs, or M&A without immediate debt pressure. This supports multi‑year development timelines common in biotech.
Platform Milestone CompletionsAchieving platform validation milestones strengthens the pipeline's technical credibility and raises probability of INDs, partnerships, and licensing. Platform progress is a structural catalyst that can convert preclinical assets into clinical programs and commercial candidates over years.
U.S. Facilities And Operations Center PlansBuilding U.S. operational infrastructure improves regulatory engagement, trial execution and commercial readiness. A permanent U.S. footprint enhances long‑term access to clinical collaborators, talent, and payer markets critical for sustainable commercialization.
Bears Say
Declining Gross Margin And Negative ProfitabilitySustained margin deterioration erodes core earnings power and means the company must generate materially higher revenue to reach breakeven. Negative EBIT/EBITDA indicate operations are not yet self‑supporting, raising reliance on external funding over the medium term.
Negative Operating And Free Cash FlowPersistent cash burn and poor cash conversion limit runway and force dependence on dilutive financing or strategic transactions. For a clinical‑stage biotech, inability to self‑fund trials materially increases execution risk and can delay development timelines.
Limited Revenue History / No Evident GrowthA nascent or inconsistent revenue base makes future cash flow projections highly uncertain and weakens negotiating leverage with partners and payers. Without demonstrated commercial traction, scaling diagnostics and therapeutics faces higher execution and reimbursement risks.
YD Bio Limited News
YDES FAQ
What was YD Bio Limited’s price range in the past 12 months?
YD Bio Limited lowest stock price was $4.73 and its highest was $25.00 in the past 12 months.
What is YD Bio Limited’s market cap?
YD Bio Limited’s market cap is $354.02M.
When is YD Bio Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were YD Bio Limited’s earnings last quarter?
Currently, no data Available
Is YD Bio Limited overvalued?
According to Wall Street analysts YD Bio Limited’s price is currently Undervalued.
Does YD Bio Limited pay dividends?
YD Bio Limited does not currently pay dividends.
What is YD Bio Limited’s EPS estimate?
YD Bio Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does YD Bio Limited have?
YD Bio Limited has 70,521,360 shares outstanding.
What happened to YD Bio Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of YD Bio Limited?
Currently, no hedge funds are holding shares in YDES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
YD Bio Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
YD Bio Limited
Breeze Holdings Acquisition Corp. operates as a clinical-stage biopharmaceutical company focuses on cancer prevention medical diagnostics and the development of exosome-based therapeutics with the potential to transform the treatment of a diseases with unmet medical need. The company is based in Taipei, Taiwan.
Scinai Immunotherapeutics
―
Aditxt
―
SciSparc Ltd.
―
CDT Equity
―
Virax Biolabs Group Ltd. Class A
―
Ownership Overview
―
Insiders
0.06% Mutual Funds
0.04% Other Institutional Investors
99.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---